In vitro activity of the New Echinocandin Antifungal, MK-0991, against common and uncommon clinical isolates of Candida species

F. Barchiesi; A. M. Schimizzi; A. W. Fothergill; G. Scalise; M. G. Rinaldi

doi:10.1007/s100960050283

In vitro activity of the New Echinocandin Antifungal, MK-0991, against common and uncommon clinical isolates of Candida species

F. Barchiesi, A. M. Schimizzi, A. W. Fothergill, G. Scalise, M. G. Rinaldi

Department of Pathology

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

A broth macrodilution method, performed as recommended by the National Committee for Clinical Laboratory Standards, was used for comparative testing of the new echinocandin antifungal agent MK-0991 and fluconazole against 50 yeast isolates belonging to 12 species of Candida. MK-0991 was shown to be highly effective against both fluconazole-susceptible and -resistant Candida spp., yielding minimum inhibitory concentrations ranging from ≤ 0.19 to 0.78 μg/ml. Fungicidal activity was exerted at ≤ 1.5 μg/ml for 73% of the isolates tested. This study suggests that MK-0991 has significant potential for clinical development.

Original language	English (US)
Pages (from-to)	302-304
Number of pages	3
Journal	European Journal of Clinical Microbiology and Infectious Diseases
Volume	18
Issue number	4
DOIs	https://doi.org/10.1007/s100960050283
State	Published - 1999

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1007/s100960050283

Cite this

@article{5a1f862447344842a3d395e5dd171add,

title = "In vitro activity of the New Echinocandin Antifungal, MK-0991, against common and uncommon clinical isolates of Candida species",

abstract = "A broth macrodilution method, performed as recommended by the National Committee for Clinical Laboratory Standards, was used for comparative testing of the new echinocandin antifungal agent MK-0991 and fluconazole against 50 yeast isolates belonging to 12 species of Candida. MK-0991 was shown to be highly effective against both fluconazole-susceptible and -resistant Candida spp., yielding minimum inhibitory concentrations ranging from ≤ 0.19 to 0.78 μg/ml. Fungicidal activity was exerted at ≤ 1.5 μg/ml for 73% of the isolates tested. This study suggests that MK-0991 has significant potential for clinical development.",

author = "F. Barchiesi and Schimizzi, {A. M.} and Fothergill, {A. W.} and G. Scalise and Rinaldi, {M. G.}",

note = "Funding Information: Acknowledgements This work was supported in part by a grant from Istituto Superiore di Sanit{\`a}, Rome, Italy (I AIDS Project, n. 50 A.0.32).",

year = "1999",

doi = "10.1007/s100960050283",

language = "English (US)",

volume = "18",

pages = "302--304",

journal = "European Journal of Clinical Microbiology and Infectious Diseases",

issn = "0934-9723",

publisher = "Vieweg",

number = "4",

}

TY - JOUR

T1 - In vitro activity of the New Echinocandin Antifungal, MK-0991, against common and uncommon clinical isolates of Candida species

AU - Barchiesi, F.

AU - Schimizzi, A. M.

AU - Fothergill, A. W.

AU - Scalise, G.

AU - Rinaldi, M. G.

N1 - Funding Information: Acknowledgements This work was supported in part by a grant from Istituto Superiore di Sanità, Rome, Italy (I AIDS Project, n. 50 A.0.32).

PY - 1999

Y1 - 1999

N2 - A broth macrodilution method, performed as recommended by the National Committee for Clinical Laboratory Standards, was used for comparative testing of the new echinocandin antifungal agent MK-0991 and fluconazole against 50 yeast isolates belonging to 12 species of Candida. MK-0991 was shown to be highly effective against both fluconazole-susceptible and -resistant Candida spp., yielding minimum inhibitory concentrations ranging from ≤ 0.19 to 0.78 μg/ml. Fungicidal activity was exerted at ≤ 1.5 μg/ml for 73% of the isolates tested. This study suggests that MK-0991 has significant potential for clinical development.

AB - A broth macrodilution method, performed as recommended by the National Committee for Clinical Laboratory Standards, was used for comparative testing of the new echinocandin antifungal agent MK-0991 and fluconazole against 50 yeast isolates belonging to 12 species of Candida. MK-0991 was shown to be highly effective against both fluconazole-susceptible and -resistant Candida spp., yielding minimum inhibitory concentrations ranging from ≤ 0.19 to 0.78 μg/ml. Fungicidal activity was exerted at ≤ 1.5 μg/ml for 73% of the isolates tested. This study suggests that MK-0991 has significant potential for clinical development.

UR - http://www.scopus.com/inward/record.url?scp=0032704707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032704707&partnerID=8YFLogxK

U2 - 10.1007/s100960050283

DO - 10.1007/s100960050283

M3 - Article

C2 - 10385023

AN - SCOPUS:0032704707

SN - 0934-9723

VL - 18

SP - 302

EP - 304

JO - European Journal of Clinical Microbiology and Infectious Diseases

JF - European Journal of Clinical Microbiology and Infectious Diseases

IS - 4

ER -

In vitro activity of the New Echinocandin Antifungal, MK-0991, against common and uncommon clinical isolates of Candida species

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this